Loading stock data…
ATEC
$10.43+0.67 (+6.86%)
Market ClosedLast close May 1
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alphatec Holdings, Inc. in the Healthcare sector is trading at $10.43. The stock is currently near its 52-week low of $9.11, remaining 32.2% below its 200-day moving average. Technical signals show neutral RSI of 44 and bearish MACD signal, explaining why ATEC maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 44) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$10.43
Potential Upside
5%
Whystock Fair Value$10.95
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$24.25+132.5%
Range$20.00 – $28.00
Fundamentals
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, ima...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.55B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.12
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1336.01%
Volume
Today's trading volume
2.85M
Recent News
3 Growth Companies With High Insider Ownership Growing Earnings Up To 63%
The United States market has recently experienced a notable upswing, climbing 3.6% in the last week and showing a robust 39% increase over the past year, with earnings projected to grow by 16% annually in the coming years. In this favorable environment, growth companies with high insider ownership can be particularly appealing as they often demonstrate strong confidence from those who know the business best and have vested interests in its success.
The ‘New’ Layer in the Market: How We Scored a 300% Trade on Polymarket Hype
There’s one reason most traders struggle during earnings season… They focus on headlines. Revenue beats. EPS misses. Conference call narratives.InvestorPlace - Stock Market News, Stock Advice & Trading Tips That’s surface-level noise. What actually moves price is expectation — and how real capital is positioned against it. I learned that lesson the hard way. You see, I’ve been in the stock market for over 28 years. While I’ve learned the mindset of a pro trader in that span, the knowledge and in
An Alphatec VP Sold Company Shares Worth $1.4 Million. Should Investors Avoid the Stock?
This spine surgery innovator reported a notable insider sale amid a year of strong share performance.
Alphatec CFO Sells $986K in Stock With Shares Up 9% This Past Year. Here's What Investors Should Know
This spine-focused medtech firm, known for its surgical innovations, reported a notable insider sale amid ongoing portfolio expansion.
Alphatec Faces New Headwinds And Market Questions In Spinal Devices
Recent fourth quarter results for Alphatec Holdings highlighted new structural headwinds in its spinal surgery devices business. Analysis points to limitations of the Prone TransPsoas (PTP) approach, which serves only a subset of the spine surgery market. Competition in surgical robotics and advanced device features is intensifying, raising questions about Alphatec's market positioning. Alphatec Holdings (NasdaqGS:ATEC) is drawing fresh attention after recent quarterly results raised...